Tumor necrosis factor-α is not essential in endotoxin induced eye inflammation: Studies in cytokine receptor deficient mice

Journal of Rheumatology

Volumn 25, Issue 12, 1998, Pages 2408-2416

  Rosenbaum, James T ^a,b   Han, Young Bok ^c   Park, Jong Moon ^d   Kennedy, Michael ^b   Planck, Stephen R ^a,b  

^a CASEY EYE INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Ewha Womans University   (South Korea)

^d Gyeongsang National University   (South Korea)

Author keywords

Interleukin 1; Knockout mice; Lipopolysaccharides; Tumor necrosis factor; Uveitis

Indexed keywords

ENDOTOXIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; MESSENGER RNA; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; IMMUNOPATHOGENESIS; INFLAMMATORY INFILTRATE; IRIDOCYCLITIS; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; AQUEOUS HUMOR; DISEASE MODELS, ANIMAL; ENDOTOXINS; FEMALE; GENE EXPRESSION; INTERFERON TYPE II; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; KERATINOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, ANTERIOR; VITREOUS BODY;

EID: 0010974218     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Rosenbaum JT. Systemic associations of anterior uveitis. Intl Ophthalmol Clin 1991;31:131-42.
2. Rosenbaum JT. Uveitis. An internist's view. Arch Intern Med 1989;149:1173-6.
3. Rosenbaum JT, Nozik RA. Uveitis: many diseases, one diagnosis. Am J Med 1985;79:545-7.
4. Rosenbaum JT. Characterization of uveitis associated with spondyloarthritis. J Rheumatol 1989;16:792-6.
5. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature 1980;286:611-3.
6. Li Q, Peng B, Whitcup SM, Jang SU, Chan C-C. Endotoxin induced uveitis in the mouse: Susceptibility and genetic control. Exp Eye Res 1995;61:629-32.
7. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-4.
8. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991;173:1029-32.
9. Firestein G, Boyle D, Yu C, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994;37:644-52.
10. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
11. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
12. Iademarco M, Barks J, Dean D. Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-α in cultured endothelial cells. J Clin Invest 1995;95:264-71.
13. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993;36:1681-90.
14. Elliot M, Maini R, Feldman M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
15. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
16. Bresnihan B, Lookabaugh J, Witt K, Musikic P. Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of a randomized double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996;39 Suppl:S73.
17. Bensimon C, Wakasugi N, Tagaya Y, et al. Two distinct affinity binding sites for Il-1 on human cell lines. J Immunol 1989;143:1168-74.
18. Chizzonite R, Truitt T, Kilian PO, et al. Two high-affinity interleukin 1 receptors represent separate gene products. Proc Natl Acad Sci USA 1990;86:8029-33.
19. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-5.
20. Evan TJ, Moyes D, Carpenter A, et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994;180:2173-9.
21. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. New Engl J Med 1996;334:1717-25.
22. Rosenbaum JT, Samples JR, Hefeneider SH, Howes EL Jr. Ocular inflammatory effects of intravitreal interleukin-1. Arch Ophthalmol 1987;105:1117-20.
23. Kulkarni PS, Mancino M. Studies on intraocular inflammation produced by intravitreal human interleukins in rabbits. Exp Eye Res 1993;56:275-9.
24. Planck SR, Huang X-N, Robertson JE, Rosenbaum JT. Cytokine mRNA levels in rat ocular tissues following systemic endotoxin treatment. Invest Ophthalmol Vis Sci 1994;35:924-30.
25. de Vos A, Klaren V, Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:3873-83.
26. Kulkarni P, Bhattacherjee P, Paterson C. Dexamethasone inhibits interleukin-1 release in endotoxin-uveitis model. Exp Eye Res 1994;58:637-8.
27. Rosenbaum JT, Boney RS. Activity of an interleukin-1 receptor antagonist in rabbit models of uveitis. Arch Ophthalmol 1992;110:547-9.
28. Rosenbaum JT, Howes EL Jr, Rubin RM, Samples JR. Ocular inflammatory effects of intravitreally injected tumor necrosis factor. Am J Pathol 1988;133:47-53.
29. De Vos AF, van Haren MAC, Verhagen C, Hoekzema R, Kijlstra A. Tumour necrosis factor-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res 1995;60:199-207.
30. de Vos A, van Haren M, Verhagen C, Hoekzema R, Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:1100-6.
31. Rosenbaum JT, Boney RS. Failure to inhibit endotoxin-induced uveitis with antibodies that neutralize tumor necrosis factor. Reg Immunol 1993;5:299-303.
32. Kasner L, Chan C-C, Whitcup SM, Gery I. The paradoxical effect of tumor necrosis factor alpha in endotoxin-induced uveitis [abstract]. Invest Ophthalmol Vis Sci 1993;34:2911-7.
33. Rosenbaum JT, Rosenbaum SO, Waldman ML, et al. Failure to inhibit endotoxin-induced uveitis with soluble TNF receptors. Reg Immunol 1994;6:73-5.
34. De Vos AF, Van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp Eye Res 1995;61:667-75.
35. Glaccum MB, Stocking KL, Charrier K, et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol 1997;159:3364-71.
36. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-52.
37. Matsumoto M, Mariathasan S, Nahm MH, Beranyay F, Peschon JJ, Chaplin DD. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science 1996;271:1289-91.
38. Pasparakis M, Alexopoulou L, Grell M, Pfizenmaier K, Bluethmann H, Kollias G. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55 kDa receptor. Proc Natl Acad Sci USA 1997;94:6319-23.
39. Planck SR, Dang TT, Graves D, Tara D, Ansel JC, Rosenbaum JT. Retinal pigment epithelial cells secrete interleukin-6 in response to interleukin-1. Invest Ophthalmol Vis Sci 1992;33:78-82.
40. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
41. Hecker KH, Roux KH. High and low annealing temperatures increase both specificity and yield. BioTechniques 1996;20:478-85.
42. Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med 1995;181:607-17.
43. Feys J, Emond JP, Salvanet-Bouccara A, Dublanchet A. Interleukin-6 and other cytokines in the aqueous humor in uveitis and endophthalmitis. J Fr Ophtalmol 1994;17:634-9.
44. Hoekzema R, Murray PI, Kijlstra A. Cytokines and intraocular inflammation. Curr Eye Res 1990;9:207-11.
45. de Boer JH, Van Haren MA, de Vries-Knoppert WA, et al. Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr Eye Res 1992;11 Suppl:181-6.
46. Hoekzema R, Murray PI, van Haren MAC, Helle M, Kijlstra A. Analysis of interleukin-6 in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1991;32:88-95.
47. Murray PI, Hoekzema R, van Haren MAC, de Hon FD, Kijlstra A. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci 1990;31:917-20.
48. Rosenbaum JT, Angell EM. Paradoxical effects of interleukin-10 in endotoxin-induced uveitis. J Immunol 1995;155:4090-4.
49. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997;27:1743-50.
50. Kondo S, Sauder DN. Tumor necrosis factor (TNF) receptor type I (p55) is a main mediator for TNF-α induced skin inflammation. Eur J Immunol 1997;27:1713-8.
51. Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxin shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-67.
52. Rothe J, Lessiaur W, Lotscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by listeria monocytogenes. Nature 1993;364:798-802.
53. Salkowski CA, Detore G, McNally R, Van Rooijen N, Vogel SN. Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo. J Immunol 1997;158:905-12.
54. Jacob CO, McDevitt HO. Tumor necrosis factor-α in murine autoimmune "lupus" nephritis. Nature 1988;331:356-7.
55. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/W F1 mice. Clin Immunol Immunopathol 1989;52:421-34.
56. Leon LR, Kozak W, Peschon J, Kluger MJ. Exacerbated febrile responses to LPS, but not turpentine, in TNF double receptor-knockout mice. Am J Physiol 1997;272:R563-9.
57. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997;94:8093-8.
58. Jacob CO, Aiso S, Michie SA, McDevitt HO, Archa-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor(TNF): similarities between TNF-α and interleukin 1. Proc Natl Acad Sci USA 1990;87:968-72.
59. Yang X-D, Tisch R, Singer SM, et al. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994;180:995-1004.
60. Smith JR, Hart PH, Coster DJ, Williams KA. Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1998;39:658-61.
61. Leon LR, Conn CA, Glaccum M, Kluger MJ. IL-1 type I receptor mediates acute phase response to turpentine, but not lipopolysaccharide, in mice. Am J Physiol 1996;271:R1668-75.
62. Norman JG, Fink GW, Sexton C, Carter G. Transgenic animals demonstrate a role for the IL-1 receptor in regulating IL-1β gene expression at steady-state and during the systemic stress induced by acute pancreatitis. J Surg Res 1996;63:231-6.
63. Kozak W, Zheng H, Conn CA, Soszynski D, Van der Ploeg LHT, Kluger MJ. Thermal and behavioral effects of lipopolysaccharide and influenza in interleukin-1β deficient mice. Am J Physiol 1995;269:R969-77.
64. Zheng H, Fletcher D, Kozak W, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1β deficient mice. Immunity 1995;3:9-19.
65. Fantuzzi G, Sacco S, Ghezzi P, Dinarello CA. Physiological and cytokine responses in IL-1 beta deficient mice after zymosan-induced inflammation. Am J Physiol 1997;273:R400-6.
66. Fantuzzi G, Dinarello CA. The inflammatory response in interleukin-1β deficient mice: comparison with other cytokine-related knockout mice. J Leukoc Biol 1996;59:489-93.